2024
Risk prediction for clonal cytopenia: multicenter real-world evidence
Xie Z, Komrokji R, Al Ali N, Regelson A, Geyer S, Patel A, Saygin C, Zeidan A, Bewersdorf J, Mendez L, Kishtagari A, Zeidner J, Coombs C, Madanat Y, Chung S, Badar T, Foran J, Desai P, Tsai C, Griffiths E, Al Malki M, Amanam I, Lai C, Deeg H, Ades L, Arana Yi C, Osman A, Dinner S, Abaza Y, Taylor J, Chandhok N, Soong D, Brunner A, Carraway H, Singh A, Elena C, Ferrari J, Gallì A, Pozzi S, Padron E, Patnaik M, Malcovati L, Savona M, Al-Kali A. Risk prediction for clonal cytopenia: multicenter real-world evidence. Blood 2024, 144: 2033-2044. PMID: 38996210, DOI: 10.1182/blood.2024024756.Peer-Reviewed Original ResearchMyeloid neoplasmsIncidence of MNClonal cytopeniaCumulative incidencePlatelet count <High-risk mutationsCox proportional hazards modelsVariant allele fractionProportional hazards modelClinical trial designCCUS patientsStratify patientsGray's testC-indexDisease entityRisk groupsCytopeniasAllele fractionSomatic mutationsRisk factorsHigh riskNatural historyRisk scoreHazards modelPatients
2023
A Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Bewersdorf J, Derkach A, Masarova L, Pemmaraju N, Stein E, Mauro M, Rampal R, Bose P. A Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. Blood 2023, 142: 6440. DOI: 10.1182/blood-2023-174322.Peer-Reviewed Original ResearchDuration of responseMaximum tolerated doseDose of ruxolitinibCDK4/6 inhibitorsStable doseTolerated doseHormone receptor-positive metastatic breast cancerRisk of progression to acute myeloid leukemiaSymptom scoresPhase I dose-escalation trialProgression to acute myeloid leukemiaTreatment of hormone receptor-positive metastatic breast cancerAbsolute neutrophil count <Cancer CenterCombination of CDK4/6 inhibitorsUS FDAMemorial Sloan Kettering Cancer CenterGrade 1 diarrheaMedian overall survivalPre-study doseDose-limiting toxicityMD Anderson Cancer CenterBone marrow fibrosisNeutrophil count <Platelet count <